×
About 2,295 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  776 results

Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with ...
https://doi.org/10.1111/jcpt.13585
Journal of Clinical Pharmacy and Therapeutics; Dickter JK, Ross JA et. al.

Jan 14th, 2022 - Management of pan-resistant cytomegalovirus infection (CMVi) requires a multifaceted approach, including host defence optimization by reducing immunosuppression, and standard or experimental antiviral therapy. A 36-year-old man with anaplastic lym...

Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precu...
https://doi.org/10.1182/bloodadvances.2021005884
Blood Advances; Iyer A, Hennessey DC et. al.

Jan 12th, 2022 - Mature T-cell lymphomas (TCLs) are rare, clinically heterogeneous hematologic cancers of high medical need. TCLs have inferior prognosis which is attributed to poor understanding of their pathogenesis. Based on phenotypic similarities between norm...

Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervo...
https://doi.org/10.1097/PAS.0000000000001859
The American Journal of Surgical Pathology; Yim J, Koh J et. al.

Jan 5th, 2022 - Primary central nervous system lymphoma (PCNSL) of peripheral T-cell lineage (T-PCNSL) is rare, and its genetic and clinicopathologic features remain unclear. Here, we present 11 cases of T-PCNSL in immunocompetent individuals from a single instit...

Cost and clinical benefit of imaging surveillance after treatment for breast implant-as...
https://doi.org/10.1016/j.ejso.2021.12.463
European Journal of Surgical Oncology : the Journal of Th... O'Connell RL, Sharma B et. al.

Jan 4th, 2022 - Recent UK guidelines recommend that surveillance imaging should not be offered to patients who have undergone treatment for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) unless clinically indicated. The aim of this study was ...

Primary Cutaneous Anaplastic Large Cell Lymphoma With 6p25.3 Rearrangement and Epidermo...
https://doi.org/10.1097/DAD.0000000000002084
The American Journal of Dermatopathology; Dutra E, Maia T et. al.

Dec 31st, 2021 - Primary cutaneous anaplastic large cell lymphoma may harbor a 6p25.3 rearrangement, which has been associated with an epidermotropic small cell component. We report the case of a patient with said lymphoma harboring that rearrangement. It presente...

see more →

Guidelines  5 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneo...
https://doi.org/10.1111/j.1365-2141.2011.08651.x
British Journal of Haematology; Dearden CE, Johnson R et. al.

Apr 13th, 2011 - The peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cell neoplasms are included in this group. The Wor...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  23 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Dec 14th, 2021 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01909934

Oct 1st, 2021 - This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Vinorelbine for Recurrent ALCL-2017
https://clinicaltrials.gov/ct2/show/NCT03443128

Jul 30th, 2021 - Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL e...

Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL)
https://clinicaltrials.gov/ct2/show/NCT02572453

Jul 21st, 2021 - PRIMARY OBJECTIVE: I. Overall response rate (ORR) to single agent AT13387 (onalespib) as measured by the proportion of partial and complete responses (PR + CR) in patients with relapsed/refractory ALK positive (+) anaplastic large cell lymphoma (A...

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
https://clinicaltrials.gov/ct2/show/NCT01578499

Jan 5th, 2021 - The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have CD30+ cutaneous T-cell lymphoma (mycosis fungoides and primary cutaneous anaplastic large cell lymphoma). This study wi...

see more →

News  112 results

Duvelisib plus Romidepsin Displays Activity in R/R PTCL
https://www.onclive.com/view/duvelisib-plus-romidepsin-displays-activity-in-r-r-ptcl

Dec 13th, 2021 - The combination of duvelisib (Copiktra) plus romidepsin (Istodax; DR) was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma (PTCL), according to final results from the dose expansion stage of a phase 1 trial (NCT027836...

Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work
https://www.medscape.com/viewarticle/961710

Oct 27th, 2021 - Takeda Pharmaceuticals is now the latest pharmaceutical company to offer a value-based agreement on one of its new targeted therapies. The rebate offer is for brigatinib (Alunbrig) which is approved for the treatment of adults with anaplastic lymp...

Brentuximab Vedotin Combos Among Key Advances in Hodgkin, T-Cell Lymphoma
https://www.onclive.com/view/brentuximab-vedotin-combos-among-key-advances-in-hodgkin-tcell-lymphoma

Oct 6th, 2021 - Alison J. Moskowitz, MD Following separate indications of brentuximab vedotin (Adcetris) for the treatment of patients with Hodgkin and T-cell lymphoma, investigators are continuing to dissect the role of the antibody-drug conjugate within each o...

ALK Inhibitor Success Prompts Search for a Role Beyond NSCLC
https://www.onclive.com/view/alk-inhibitor-success-prompts-search-for-a-role-beyond-nsclc

Aug 25th, 2021 - The rapid development of novel agents directed at anaplastic lymphoma kinase (ALK) gene fusions has emerged as one of the success stories of the targeted therapy era in non–small cell lung cancer (NSCLC).1,2 However, oncogenic activation of ALK, t...

Nodule on the Neck
https://www.mdedge.com/dermatology/article/239893/dermatopathology/nodule-neck
Malan Kern, MD, Kelsey Parks, BS et. al.

May 11th, 2021 - The Diagnosis: Primary Cutaneous Anaplastic Large Cell Lymphoma Microscopic analysis showed a dense proliferation of mononuclear cells filling and expanding the dermis with focal epidermotropism (Figure 1). Immunohistochemistry demonstrated strong.

see more →